The FDA Law Blog

SEPTEMBER 17, 2024

By Sarah Wicks & Dara Katcher Levy — FDA’s Office of Prescription Drug Promotion (OPDP) has issued its fourth Untitled Letter of 2024 – this one to AbbVie, Inc. The approved labeling for UBRELVY includes a warning and precaution regarding hypersensitivity reactions, with the most common adverse reactions being nausea and somnolence.

Labelling 59

Labelling Adverse Reactions Dosage 59

The Checkup by Singlecare

FEBRUARY 6, 2024

While some interactions may be mild, others may lead to serious side effects or adverse reactions. Here are some common steps to take: Check the label : Always read the drug information in the product package for potential warnings, and follow the instructions on your prescription label for the appropriate dosage.

Adverse Reactions 52

Adverse Reactions Labelling Packaging Dosage 52

The Checkup by Singlecare

FEBRUARY 11, 2025

For anyone considering Wegovy, its important to know all the potential adverse reactions before starting treatment, plus how to avoid and manage them. A study in Obesity Reviews from 2024 found that semaglutides adverse effects were typically mild or moderate, not serious. Fortunately, weve got all that info right here.

Dosage 52

Dosage Adverse Reactions Hospitals FDA 52

The Checkup by Singlecare

DECEMBER 12, 2024

That has led to some people taking it off-label (for a non-FDA-approved use) for weight lossat least until the FDA approved Wegovy specifically for weight loss in 2021. A compounded drug is any formulation of a drug that has not been produced by its original manufacturer under an official generic or brand-name label.

Compounding 52

Compounding Compounding Pharmacies FDA Insurance 52

The Thyroid Pharmacist

MARCH 7, 2025

to fluoride in my tap water, to hidden mold in my home, to my shampoo and deodorant (have you ever read those labels?!), 7] A recent report from 2024 found that fluoride exposure is associated with lower IQ in children, which has brought the issue of fluoridation front and center again (the U.S.

Health and Personal Care Stores 61

Health and Personal Care Stores Labelling Immunization Packaging 61

The Checkup by Singlecare

NOVEMBER 4, 2024

As of June 2024, the FDA Adverse Event Reporting System (FAERS) Public Dashboard shows 57 patient or healthcare provider reports of hair loss (alopecia) during Nurtec ODT use. In comparison, 41% of submissions about Nurtec reported that the drug was ineffective, while nearly 10% reported nausea as an adverse reaction.

Adverse Reactions 52

Adverse Reactions FDA Labelling 52